Neurodegenerative Disease Market Size is valued at 44.51 Billion in 2024 and is predicted to reach 71.67 Billion by the year 2034 at a 5.0% CAGR during the forecast period for 2025-2034.
It is anticipated to record a CAGR of 4.3% between 2022 and 2030.An umbrella term for a range of conditions that affect neurons in the human brain are referred to as neurodegenerative diseases. Neurons normally don’t replace or reproduce themselves, so when they become damaged or die, they cannot be replaced by the body. Neurodegenerative diseases are incurable and debilitating conditions that result in progressive degeneration and/or death of nerve cells. Degenerative nerve diseases include Alzheimer's disease, amyotrophic lateral sclerosis, Friedreich's ataxia, huntington’s disease, Lewy body disease, Parkinson's disease, spinal muscular atrophy.
The market of neurodegenerative disease is boosted by the rising awareness among people and the research and developmental activities undertaken by various research institutions and companies to develop effective therapies to treat them. However, the complex nature of the diseases and the lack of knowledge about their causative factors in most cases hamper the advancement of research and development into effective treatment methods. Current therapies only help to alleviate symptoms rather than curing. Due to rapidly increasing prevalence, Alzheimer's disease and Parkinson's disease pose to be the most challenging diseases. Entry of generics to the already existing products can be a challenge to the market. Reformulating marketed drugs shall provide great opportunities to the neurodegenerative disease market.
The Global market for neurodegenerative disease is fragmented into its drug class and indications. Based on the drug class, the global market is segregated into NMDA, dopamine inhibitors, and SSRIs. On the basis of indications, the market is categorized into Huntington disease, Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, and amyotrophic lateral sclerosis. The market is also segmented based on the region Americas, the EMEA, and the APAC.
Some of the molecules under development include VY AADC is gene therapy from Voyager Therapeutics, which is in phase 2 stage of development for the treatment of Parkinson's disease, Crenezumab of Roche is in Phase 3 for Alzheimer’s disease, Gocovri, Ingrezza , Radicava are some of the products approved in 2017 for neurodegenerative diseases.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 44.51 Billion |
| Revenue Forecast In 2034 | USD 71.67 Billion |
| Growth Rate CAGR | CAGR of 5.0% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Billion and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Drug Class, By Applications |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; South Korea; South East Asia |
| Competitive Landscape | Novartis, Pfizer, Merck Serono, Biogen Idec, TEVA, UCB, Boehringer Ingelheim, Sanofi, GlaxoSmithKline, and others |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Neurodegenerative Disease Market Snapshot
Chapter 4. Global Neurodegenerative Disease Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Drug Class Estimates & Trend Analysis
5.1. By Drug Class & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Drug Class:
5.2.1. NMDA
5.2.2. SSRIs
5.2.3. Decarboxylase inhibitors
5.2.4. Cholinesterase Inhibitors
5.2.5. Immunomodulators
5.2.6. Dopamine Inhibitors
Chapter 6. Market Segmentation 2: By Application Estimates & Trend Analysis
6.1. By Application & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Application:
6.2.1. Parkinson’s Disease
6.2.2. Huntington Disease
6.2.3. Amyotrophic Lateral Sclerosis
6.2.4. Alzheimer’s Disease
Chapter 7. Neurodegenerative Disease Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Neurodegenerative Disease Market revenue (US$ Million) estimates and forecasts By Drug Class, 2021 - 2034
7.1.2. North America Neurodegenerative Disease Market revenue (US$ Million) estimates and forecasts By Application, 2021 - 2034
7.1.3. North America Neurodegenerative Disease Market revenue (US$ Million) estimates and forecasts by country, 2021 - 2034
7.2. Europe
7.2.1. Europe Neurodegenerative Disease Market revenue (US$ Million) By Drug Class, 2021 - 2034
7.2.2. Europe Neurodegenerative Disease Market revenue (US$ Million) By Application, 2021 - 2034
7.2.3. Europe Neurodegenerative Disease Market revenue (US$ Million) by country, 2021 - 2034
7.3. Asia Pacific
7.3.1. Asia Pacific Neurodegenerative Disease Market revenue (US$ Million) By Drug Class, 2021 - 2034
7.3.2. Asia Pacific Neurodegenerative Disease Market revenue (US$ Million) By Application, 2021 - 2034
7.3.3. Asia Pacific Neurodegenerative Disease Market revenue (US$ Million) by country, 2021 - 2034
7.4. Latin America
7.4.1. Latin America Neurodegenerative Disease Market revenue (US$ Million) By Drug Class, (US$ Million)
7.4.2. Latin America Neurodegenerative Disease Market revenue (US$ Million) By Application, (US$ Million)
7.4.3. Latin America Neurodegenerative Disease Market revenue (US$ Million) by country, (US$ Million) 2021 - 2034
7.5. Middle East & Africa
7.5.1. Middle East & Africa Neurodegenerative Disease Market revenue (US$ Million) By Drug Class, (US$ Million)
7.5.2. Middle East & Africa Neurodegenerative Disease Market revenue (US$ Million) By Application, (US$ Million)
7.5.3. Middle East & Africa Neurodegenerative Disease Market revenue (US$ Million) by country, (US$ Million) 2021 - 2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Novartis
8.2.2. Pfizer
8.2.3. Merck Serono
8.2.4. Biogen Idec
8.2.5. TEVA
8.2.6. UCB
8.2.7. Boehringer Ingelheim
8.2.8. Sanofi
8.2.9. GlaxoSmithKline
8.2.10. Other Key Players
Global Neurodegenerative Disease Market by Drug Class
Global Neurodegenerative Disease Market by Application
Global Neurodegenerative Disease Market by Region
North America
Asia Pacific
Latin America
Middle East & Africa